Investor Presentaiton
Segment operating profit
(Excludes shared/non-allocated costs)
Chronic Care
Ostomy and Continence Care
Interventional Urology
Wound & Skin Care
59
58
58
57
58
2,500
2,397
2,456
2,375
2,476
35
Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23 Q3 22/23
Segment Operating Profit DKKm
Segment Operating Profit Margin (%)
Voice & Respiratory Care
2
37
36
35
35
42
22
38
39
37
37
56
239
244
235
236
289
291
32
A
32
33
34
A
35
222
261
262
249
148
156
162
171
143
Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23 Q3 22/23
Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23 Q3 22/23
57
58
59
59
58
9,586
8,774
8,318
41
39
39
40
40
7,798
7,307
37
38
36
35
35
1,029
1,089
914
941
818
860
802
728
715
654
Q3 21/22 Q4 21/22 Q1 22/23 Q2 22/23 Q3 22/23
32
34
32
489
•
383
FY 18/19 FY 19/20 FY 20/21 FY 21/22 YTD 22/23
FY 18/19 FY 19/20 FY 20/21 FY 21/22 YTD 22/23
FY 18/19 FY 19/20 FY 20/21 FY 21/22 YTD 22/23
FY 21/22 YTD 22/23
•
•
Voice & Respiratory Care is
Coloplast's new business
area, added with the
acquisition of Atos Medical.
FY 21/22 includes eight
months of impact.
Segment operating profit
for Voice & Respiratory
Care is excluding PPA
amortisation expenditures.
R&D costs for Interventional Urology and Voice and Respiratory Care are included in the segment operating profit/loss for the respective segments, while R&D costs for Chronic Care and Wound and Skin Care are shared between functions and
included under shared/non-allocated costs.
Financial items and income tax are not allocated to operating segments.
67
ColoplastView entire presentation